Docoh
Loading...

ATXI Avenue Therapeutics

News

From Benzinga Pro
12 Health Care Stocks Moving In Monday's Intraday Session
29 Nov 21
Intraday Update, Markets, Movers
Avenue Therapeutics Announces FDA Advisory Committee Meeting To Review IV Tramadol NDA Tentatively Scheduled For February 15, 2022
29 Nov 21
News, FDA
Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue” or the “Company”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the
76 Biggest Movers From Yesterday
11 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share.
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 Nov 21
Intraday Update, Markets, Movers
55 Stocks Moving In Wednesday's Mid-Day Session
10 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers RenovoRx, Inc. (NASDAQ: RNXT) shares jumped 128% to $12.41. The company, on Tuesday evening, made a presentation on intra-arterial chemotherapy as a potential innovative treatment for pancreatic cancer.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
10 Nov 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
30 Stocks Moving in Wednesday's Pre-Market Session
10 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers RenovoRx, Inc. (NASDAQ: RNXT) rose 113% to $11.50 in pre-market trading. The company, on Tuesday evening, made a presentation on intra-arterial chemotherapy as a potential innovative treatment for pancreatic cancer.
12 Health Care Stocks Moving In Monday's Intraday Session
25 Oct 21
Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Monday's Pre-Market Session
25 Oct 21
Pre-Market Outlook, Markets, Movers
Avenue Therapeutics Receives Interim Response To Its Formal Dispute Resolution Request From US Food And Drug Administration Office Of New Drugs
25 Oct 21
Biotech, News, FDA, General
Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that it has received a written interim
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
8 Oct 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
7 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
6 Oct 21
Biotech, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
5 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep 21
Biotech, Earnings, M&A, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29)
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep 21
Biotech, M&A, News, Penny Stocks, Offerings, Small Cap, FDA, Legal, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

Press releases

From Benzinga Pro
Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Option
17 Nov 21
News, Financing, Press Releases
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the "Company") (NASDAQ:ATXI), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that the
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
12 Nov 21
News, Press Releases
NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI).About Avenue TherapeuticsAvenue
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
12 Nov 21
Markets, Press Releases
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the "Company") (NASDAQ:ATXI), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced the
Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
9 Nov 21
News, IPOs, Press Releases
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced the pricing of an
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
25 Oct 21
Press Releases, General
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that it has